AtriCure (ATRC)
Makes surgical cardiac ablation, AtriClip appendage exclusion, and cryo nerve block devices.
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.
A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76. This price is within a 52-week range of $25.36 to $43.18, re
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.
AtriCure Q2 Earnings Call Highlights
AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.
AtriCure Reports Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu.
AtriCure to Announce Second Quarter 2026 Financial Results
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a
AtriCure to Announce Second Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listeni.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested.
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript